Dorzolamide for Glaucoma
Dorzolamide is a topical carbonic anhydrase inhibitor indicated for reducing intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension, typically as adjunctive therapy when beta-blockers alone are insufficient, with dosing of one drop three times daily as monotherapy or twice daily when combined with timolol. 1
Indications
Dorzolamide is FDA-approved for:
- Open-angle glaucoma (primary or secondary)
- Ocular hypertension in patients insufficiently responsive to beta-blockers 1
The drug works by inhibiting carbonic anhydrase II in the ciliary epithelium, thereby reducing aqueous humor production and lowering IOP 2.
Dosing Regimen
Monotherapy:
Combination therapy (dorzolamide/timolol fixed combination):
- One drop twice daily in the affected eye(s) 1
- When using multiple topical ophthalmic drugs, administer at least 10 minutes apart 1
Efficacy Profile
Dorzolamide demonstrates moderate IOP-lowering efficacy:
- IOP reduction: 15-20% from baseline 2
- Mean IOP reduction of approximately 4-6 mm Hg at peak (2 hours post-dose) and 3-4.5 mm Hg at trough (8 hours post-dose) 3
- Efficacy is less than prostaglandin analogs but comparable to beta-blockers 5
- Provides excellent additive effect when combined with beta-blockers, with an additional 14-15% IOP reduction 6
The 2021 guideline evidence confirms that prostaglandin analogs remain superior for IOP lowering compared to dorzolamide 5. However, dorzolamide serves as an important alternative when prostaglandins are contraindicated or as adjunctive therapy.
Contraindications
Absolute contraindication:
- Sulfonamide allergy 2
This is critical because dorzolamide is a sulfonamide derivative and can trigger severe allergic reactions including Stevens-Johnson syndrome in susceptible patients.
Common Adverse Effects
Most frequent (occurring in up to 30% of patients):
Moderate frequency (5-15% of patients):
- Conjunctival hyperemia
- Blurred vision
- Superficial punctate keratitis
- Eye itching 1
Less common but notable (1-5%):
- Conjunctivitis
- Corneal edema (particularly in patients with borderline endothelial function) 7
- Allergic dermatitis/conjunctivitis
- Metallic taste 2
Discontinuation rate: Approximately 5% of patients discontinue therapy due to adverse effects, with conjunctivitis being the most common reason 1.
Clinical Positioning
Based on the 2021 AAO Preferred Practice Pattern guidelines 2:
Dorzolamide is NOT first-line therapy. Prostaglandin analogs remain the preferred initial medical therapy due to superior efficacy, once-daily dosing, and better tolerability.
Use dorzolamide when:
- Prostaglandin analogs are contraindicated or not tolerated
- Beta-blockers are contraindicated (asthma, COPD, heart block, bradycardia)
- Additional IOP lowering is needed as adjunctive therapy
- Patient requires preservative-free formulation (newer formulations available) 8
Important Clinical Considerations
Advantages over oral carbonic anhydrase inhibitors:
- No systemic acid-base disturbances
- No electrolyte imbalances
- No risk of renal calculi, aplastic anemia, or blood dyscrasias
- Better tolerability profile 3, 4
Advantages over other topical agents:
- Does not cause miosis (unlike pilocarpine)
- No cardiovascular or pulmonary contraindications (unlike beta-blockers)
- Excellent additivity with other glaucoma medications 7
Common pitfall: Patients with compromised corneal endothelium may develop corneal edema with dorzolamide use. Evaluate corneal endothelial function before initiating therapy in patients with corneal disease or previous intraocular surgery 7.
Pregnancy category: C - use only if potential benefit justifies potential risk to fetus 2
Target IOP and Monitoring
When initiating dorzolamide therapy, establish a target IOP approximately 20% lower than baseline mean IOP measurements 2. However, if baseline IOP is markedly elevated, a 20% reduction may be insufficient. Reassess target IOP at each visit based on optic nerve status and visual field stability.